Lantheus Holdings (LNTH) EBT Margin (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly EBT Margin of 41.45% for Q1 2026, up 1555.0% year-over-year from 2.5% in Q1 2025, and up 119.44% quarter-over-quarter from 18.89% in Q4 2025.
Lantheus Holdings (LNTH) EBT Margin (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported EBT Margin for 13 consecutive years, with 41.45% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT Margin rose 1555.0% year-over-year to 41.45%; the TTM figure through Mar 2026 stood at 24.59% (up 2938.0% YoY), while the FY2025 annual figure was 20.77%, up 2070.0% from the prior year.
- EBT Margin grew to 41.45% in Q1 2026 per LNTH's latest filing, from 18.89% in the prior quarter.
- Across five years, EBT Margin topped out at 922.69% in Q4 2023 and bottomed at 110.12% in Q4 2024.
- Historically, EBT Margin has averaged 68.21% across 5 years, with a median of 27.72% in 2022.
- Annual changes were most pronounced in 2023 — EBT Margin surged 98966 bps — and 2024, when it slumped 103280 bps.
- Lantheus Holdings' EBT Margin stood at 66.97% in 2022, then jumped by 1478 bps to 922.69% in 2023, then plunged by 112 bps to 110.12% in 2024, then jumped by 117 bps to 18.89% in 2025, then soared by 119 bps to 41.45% in 2026.
- Business Quant data shows LNTH's EBT Margin at 41.45% in Q1 2026, 18.89% in Q4 2025, and 11.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 24.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.17% |
| Mar 31, 2026 | 41.45% |
| Dec 31, 2025 | 18.89% |
| Sep 30, 2025 | 11.04% |
| Jun 30, 2025 | 27.65% |
| Mar 31, 2025 | 25.90% |
| Dec 31, 2024 | -110.12% |
| Sep 30, 2024 | 46.50% |
| Jun 30, 2024 | 21.41% |
| Mar 31, 2024 | 46.29% |
| Dec 31, 2023 | 922.69% |
| Sep 30, 2023 | 49.99% |
| Jun 30, 2023 | 38.45% |
| Mar 31, 2023 | -3.69% |
| Dec 31, 2022 | -66.97% |
| Sep 30, 2022 | 34.69% |
| Jun 30, 2022 | 27.73% |
| Mar 31, 2022 | 27.72% |
| Dec 31, 2021 | -31.65% |
| Sep 30, 2021 | -19.43% |